Objectives: To evaluate treatment results for varicose great saphenous vein (GSV) using endovenous laser ablation (EVLA) in an ambulatory single center.
Material And Methods: We prospectively studied 77 limbs with varicose GSV in 74 patients who were treated using 980-nm EVL with a 600-mm laser fiber and the power settings of 10-25 Watts. The patients were followed using color Doppler ultrasound.
Results: Continued closure of treated GSV was found in 98.3% of the legs evaluated at 3-week follow-up (n = 60). At 3- and 6-month intervals, 94.1% and 97% successful occlusion was achieved, respectively. The main complications of the procedure included prolonged leg pain (2 cases), hyperestheasia (one case) and lidocaine sensitivity (one case).
Conclusion: EVLA treatment of the GSV is a safe and highly effective method accompanied with few complications in midterm follow-up. It is feasible in ambulatory settings and the patients return to their daily activities early after intervention.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/1538574408326182 | DOI Listing |
Eur J Vasc Endovasc Surg
January 2025
Department of Phlebology, Skin and Vein Clinic Oosterwal, Alkmaar, the Netherlands.
Objective: The aim of this study was to compare anterior accessory saphenous vein (AASV) reflux after standard endovenous laser ablation (EVLA) vs. flush EVLA (fEVLA) of the great saphenous vein (GSV).
Methods: This was as randomised, single blind, controlled trial (Dutch Trial Register, NL5283).
Sci Rep
January 2025
Department of Vascular Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, 210009, China.
To retrospectivly investigate the short-term clinical outcomes of one-stop and two-staged endovenous laser ablation (EVLA) procedures for treatment of varicose veins (VVs) and iliac vein compression syndrome (IVCS). In this study, 424 patients were treated for VVs and IVCS from June 2017 to June 2020, 91 underwent one-stop stent angioplasty (SA) and EVLA, 132 underwent two-staged SA and EVLA, 104 underwent one-stop balloon angioplasty (BA) and EVLA, and 97 underwent two-staged BA and EVLA. Clinical outcomes and complications were recorded at 3 and 12 months post-intervention.
View Article and Find Full Text PDFAnn Vasc Surg
December 2024
Department of Vascular Surgery, Aristotle University of Thessaloniki, AHEPA University General Hospital, Thessaloniki, Greece.
Purpose: To assess the safety and efficacy of flush endovenous laser ablation (fEVLA) in the treatment of chronic venous insufficiency.
Materials And Methods: Following the PRISMA 2020 guidelines, a systematic review aiming to identify studies published from inception to March 2024 was conducted. The investigation covered single-arm studies and studies comparing fEVLA to standard EVLA (sEVLA).
Ann Vasc Dis
December 2024
This is an annual report indicating the number and early clinical results of annual vascular treatment performed by vascular surgeons in Japan in 2017, as analyzed by Database Management Committee (DBC) members of the Japanese Society for Vascular Surgery (JSVS). To survey the current status of vascular treatments performed by vascular surgeons in Japan, the DBC members of the JSVS analyzed the vascular treatment data provided by the National Clinical Database, including the number of treatments and early results such as operative and hospital mortality. In total, 137,909 vascular treatments were registered by 1,076 institutions in 2017.
View Article and Find Full Text PDFAnn Vasc Dis
December 2024
Department of Cardiovascular Surgery, Nippon Medical School Hospital, Tokyo, Japan.
This study aimed to quantitatively evaluate peripheral nerve injury (PNI) after varicose vein (VV) surgery using endovenous laser ablation (EVLA). Overall, 25 cases were analyzed. All patients underwent EVLA of the great saphenous vein (GSV) with or without resection of the varix of the GSV tributaries in stab and avulsion fashion (microphlebectomy).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!